



## Press Release

### **Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer**

**Maastricht, The Netherlands, November 7, 2019** -- [Epify BV](#) is a recently established biotechnology company that translates sound epigenetic biomarker discoveries into clinical practice to help doctors improve the early diagnosis and treatment of cancer patients.

Epify is proud to announce that it is strengthening its management team with the appointment of Dr. Leander Van Neste as Chief Scientific Officer. In this capacity, Dr. Van Neste will lead all aspects of the implementation of Epify's scientific and technology strategy, and he will also be highly engaged in the company's scientific, clinical and industrial collaborations. Furthermore, Dr. Van Neste will lead Epify's scouting and evaluation of new epigenetic biomarker opportunities.

Joris Schuurmans, Epify's CEO, remarked "Leander is a seasoned executive with extensive experience in academia at Ghent University, Maastricht University, and Johns Hopkins. He also has a wealth of experience in the private sector with MDxHealth and miDiagnostics, including the development of MDxHealth's ConfirmMDx and SelectMDx assays. He brings a wealth of experience in the application of epigenetics for cancer diagnosis, covering such aspects as discovery, assay development, clinical validation and bioinformatics. I'm looking forward to working together with Leander to expand Epify's collaborative network in the clinical and scientific community."

Leander Van Neste, Epify's recently appointed CSO, commented "I am thrilled about the opportunity to join Epify at this exciting stage. Epigenetic biomarkers have been a promising target for less-invasive cancer diagnosis and early treatment, and they continue to be clinically underutilized. There is a wealth of experience and dormant IP in academia that can be made accessible to doctors and patients with the help of Epify and our industrial partners. Personally, I am very motivated to be part of this mission to unharness the full diagnostic power of epigenetic biomarkers."

---

#### **About Epify**

Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients. To this end Epify collaborates with academia, clinicians, professional investors and industrial molecular test providers to translate these biomarkers from sound discovery to clinical applications.



### **About Novalis**

Novalis Biotech Incubation seeds biotechnology and life sciences related companies. Novalis develops innovative investment ideas at the early stage and supports further evolution. Our investment ideas focus on the interaction between bio-informatics and life sciences. We strongly believe in applying innovative information technology to advance prevention, diagnosis, or treatment of disease. Novalis recently invested 500,000 Euros in Epify.

### **About Brightlands Maastricht Health Campus**

Brightlands Maastricht Health Campus supervises the entire process involved in the development of innovations related to health and life sciences (valorization) for scientists, researchers and students. Excellent facilities for imaging equipment contribute to the Campus' position as the ideal location for building ecosystems involving imaging, regenerative medicine and innovative diagnostics. The Brightlands Maastricht Health Campus sets itself apart by offering the complete innovation chain: fundamental and applied research, equipment, the clinic and the cross-over possibilities with the other Brightlands campuses.

### **For more information, contact:**

#### **Corporate contact:**

Joris Schuurmans  
Chief Executive Officer, Epify  
[joris@epify.nl](mailto:joris@epify.nl)

#### **Communications contact:**

MND-Partners  
PR & Communications  
[welcome@mnd-partners.com](mailto:welcome@mnd-partners.com)